about
Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968Adverse events post smallpox-vaccination: insights from tail scarification infection in mice with Vaccinia virusEPIPOX: Immunoinformatic Characterization of the Shared T-Cell Epitome between Variola Virus and Related Pathogenic OrthopoxvirusesThe mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection.Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulinImpact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity.Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.Obligatory requirement for antibody in recovery from a primary poxvirus infectionSmallpox vaccine safety is dependent on T cells and not B cellsEpidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunityEnhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless miceVaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses.Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Orthopoxvirus targets for the development of antiviral therapies.Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques.Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.Isolation and identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and vaccinia virus antiviral activity.Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.Inhibition of vaccinia virus replication by nitazoxanide.
P2860
Q24799168-8BFE7542-FB8D-4797-9B3F-B0183675335DQ27346800-CAD6F567-91C8-479A-A52B-1FA062CDE72FQ28607584-C9E4AF89-4EF9-4E9D-BEE8-F8BC8EA4063DQ30223108-167CB5AA-4B6E-4526-A79E-63C7419DB901Q33543131-A8D9F1FF-C3EF-4D34-BD25-CC5BEBE15D0BQ33843163-577078D7-6519-481D-860F-C69F95521F01Q33883711-7A6EDF5D-256F-467D-B180-D2CEC23FF96BQ34140816-A6370280-4EBC-4693-BE05-720E4BA34593Q34447009-52DD51AB-5C89-4D73-A095-FC58D8E98AA5Q34484027-5EE3DC48-1EBD-429E-B7EE-E3752728E6F8Q34502253-FF8A7336-5FE5-429E-B7CB-26C96798887FQ34676027-11DD0CE2-74E1-4AFE-8BAB-F58391A50C47Q34716960-03581270-022C-42A2-AC51-3118F31C8FF8Q34717009-A5B7FBAA-5D63-4401-857F-879102E98FA1Q34743303-AB413228-2F7C-41F4-B1DD-0B763C64E99BQ34762818-A56B7DAF-C5FC-40DF-9870-56996B9E87EEQ34922842-80BD7E00-A1E4-492C-81DD-E87639F40E37Q34991389-39B8C8DF-6E0F-4DBD-ABF5-85051CCE4CDDQ35007525-6F42B5B5-C604-4477-BE72-2425F15B359EQ35571248-A91D3C38-398D-4A44-B971-D9BAF9BE506AQ36074391-D469D447-E874-4933-BE68-3556149A6200Q36486818-9A2E7A14-4D82-449B-A9B4-C4A3785348D3Q36488876-5B9E1180-C9C9-4D12-B47D-9B30501FAC50Q36978610-A77A15D9-7C1B-4EC6-A38B-FF4BFEB65CE6Q37395140-10FF6804-4663-4DED-B98E-B88D774D1CD6Q37593480-00DCF473-144A-4879-B43D-AA8B42F9CFEDQ37596586-F6BC3645-2CD6-4132-985A-9F420DA02F23Q40249810-8AD1ED85-14B3-4D70-8142-48FC52430DECQ44801183-842BC4C8-D0F3-47A4-ACD3-EF81611AAA16Q54117207-8DEAB428-5773-4F5A-88C1-F7BB5F695B51
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Progressive vaccinia.
@ast
Progressive vaccinia.
@en
type
label
Progressive vaccinia.
@ast
Progressive vaccinia.
@en
prefLabel
Progressive vaccinia.
@ast
Progressive vaccinia.
@en
P356
P1476
Progressive vaccinia.
@en
P2093
Mary E Wright
P304
P356
10.1086/374244
P407
P577
2003-02-20T00:00:00Z